Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decided to stop the development of vilobelimab in cSCC and early terminated the IFX-1-P2.8 trial due to new alternative treatments for cSCC with high efficacy rates.

Conditions

SCC - Squamous Cell Carcinoma of Skin

Interventions

DRUG: Vilobelimab
DRUG: Vilobelimab + pembrolizumab combination therapy

Sponsor

InflaRx GmbH

Collaborators

[object Object]